Business Wire

Adtran launches Oscilloquartz Time Scale System for ultra-precise timekeeping

19.9.2024 15:00:00 EEST | Business Wire | Press release

Share

Adtrantoday launched its Oscilloquartz Time Scale System, developed to meet the precise timekeeping requirements of national metrology institutes, scientific research facilities and other applications demanding the highest levels of accuracy and traceability. The comprehensive system integrates Adtran’s Oscilloquartz grandmaster clocks, GPS/GNSS receivers and high-performance optical cesium atomic clocks, alongside a combination of phase comparator, reference generator and time interval counter, ensuring synchronization with Coordinated Universal Time (UTC) and providing robust protection against cybersecurity threats. With its customizable design, real-time monitoring and seamless transition capabilities, the Oscilloquartz Time Scale System addresses the growing demand for resilient and accurate time synchronization across various sectors, ensuring operational continuity and data integrity in an increasingly interconnected and digital world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919196894/en/

Adtran’s Oscilloquartz Time Scale System marks a major milestone for network synchronization. (Photo: Business Wire)

“The launch of our Time Scale System represents a major advancement in precision timekeeping. Leveraging our industry-first high-performance optical cesium atomic clocks and a fully integrated system capable of combining multiple clock types into a single, stable time scale, this solution offers unmatched accuracy and resilience,” said Gil Biran, GM of Oscilloquartz, Adtran. “At a time when industries like national metrology, defense and aerospace face increasing demands for precision and reliability, our Time Scale System will deliver the confidence needed for mission-critical applications. Oscilloquartz is proud to continue leading innovation in timekeeping, providing solutions that exceed the highest standards of accuracy, security and performance.”

The Oscilloquartz Time Scale System delivers exceptional timekeeping by integrating up to eight different clock types, including optical cesium atomic clocks, hydrogen maser clocks and GNSS receivers, into a single, stable time scale. It uses multi-channel measurement systems to calculate clock time differences and combine these inputs into one output. The system supports the distribution of multiple 5MHz, 10MHz, 1PPS, TOD and IRIG-B outputs, as well as NTP and PTP protocols for flexible infrastructure support. With real-time monitoring and data archiving, it ensures seamless operation during GPS/GNSS outages, maintaining nanosecond precision. The system also automatically generates BIPM reports for institutes contributing to global time standards. With its customizable design, staging, integration and compliance with local legal time providers, the Oscilloquartz Time Scale System sets a new standard in mission-critical timekeeping.

“Our Time Scale System will be key to advancing global standards in timekeeping. By offering real-time monitoring and seamless integration with existing infrastructures, the system ensures our customers stay synchronized with UTC and are protected against any potential disruptions,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, Adtran. “With its customizable and modular design, the system enables us to collaborate closely with each client to tailor a solution precisely to their specific requirements, whether they need unique frequency sources or enhanced GPS/GNSS resilience. This adaptability underscores our commitment, since our founding in 1949, to delivering technology that meets the highest standards and is versatile enough to perform in diverse and challenging environments.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240919196894/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye